Nuvectis Pharma Inc 뉴스 - NVCT | 주식 나스닥 | ADVFN

다우존스 지수

브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.

등록

Nuvectis Pharma Inc (NVCT)

7.80

0.85

(12.23%)

마감 17 2월 6:00AM

7.79

-0.01

(-0.13%)

시간외 거래: 9:59AM

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

Nuvectis Pharma (NASDAQ: NVCT) continues to make strides in precision oncology, gaining momentum following presentations last week at the...

PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch

With its focus on targeting well-defined subgroups by inhibiting SRC/YES1 kinases in Non Small-Cell Lung Cancer patients resistant to EGFR and...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

gail

grabbed some on the dip

Monksdream

Monksdream 5 월 전

Monksdream

Monksdream 7 월 전

Monksdream

Monksdream 10 월 전

Monksdream

Monksdream 11 월 전

NVCT 10Q due March 6

Monksdream

Monksdream 1 년 전

conix

conix 3 년 전

NVCT HIGHLIGHTS:

*Recently completed Initial Public Offering - $5.00 Per share
*2 Precision Cancer medicines in development - ovarian and triple negative breast
*Data flow throughout 2022
*CEO with multiple success stories in life science sector to $billion dollar market caps
*Analysts project a $66 billion precision medicines market for 2021; In 6 years, this number is expected to top $140 billion

Nuvectis Pharma Inc - Company Background:

Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for serious conditions of unmet medical need in oncology. The Company is currently developing two drug candidates: NXP800, a clinical-stage HSF1 pathway inhibitor currently in a Phase 1 study in patients with advanced solid tumors, and NXP900, a novel SRC/YES1 kinase inhibitor currently in preclinical development with IND-enabling studies ongoing.

Market Capitalization: $225 million
Range - 52 week: $3.08 - $20.75
Current Price: $20.44
Trades on: Nasdaq Capital Market
Ticker Symbol: NVCT

website: nuvectis.com

TheFinalCD

TheFinalCD 3 년 전

wow from $3 to almost $21

ipo_dude

ipo_dude 3 년 전

TheFinalCD

TheFinalCD 3 년 전

WOW $7 MOVE 3-10

CONGRAT$ NVCT

spindog

spindog 3 년 전

I feel the same

kkballa

kkballa 3 년 전

Nuvectis Pharma

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관